source
- Westlake-backed Vedana Therapeutics raises $46M to develop anti-PACAP migraine prevention drugsVedana Therapeutics, a new biotech formed out of stealth, announced it has secured $46 million in financing backed by Westlake. The capital will be used to advance its anti-PACAP antibody program a…
- Triveni Bio secures $65M Series C as second eczema candidate enters clinical trialsTriveni Bio announced a $65 million Series C financing round aimed at supporting its ongoing development programs. The round was co‑led by Ascenta Capital and Janus Henderson Investors, with parti…